BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17617763)

  • 1. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.
    de Rivas B; Luque M; Martell N; Fernández C; Fernández-Cruz A
    J Clin Hypertens (Greenwich); 2007 Jul; 9(7):530-7. PubMed ID: 17617763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone reduces blood pressure in non-dipping diabetic patients.
    Negro R; Dazzi D; Hassan H; Pezzarossa A
    Minerva Endocrinol; 2004 Mar; 29(1):11-7. PubMed ID: 15258553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
    Anan F; Masaki T; Fukunaga N; Teshima Y; Iwao T; Kaneda K; Umeno Y; Okada K; Wakasugi K; Yonemochi H; Eshima N; Saikawa T; Yoshimatsu H
    Eur J Clin Invest; 2007 Sep; 37(9):709-14. PubMed ID: 17696960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
    Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
    Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
    Charbonnel B; DeFronzo R; Davidson J; Schmitz O; Birkeland K; Pirags V; Scheen A;
    J Clin Endocrinol Metab; 2010 May; 95(5):2163-71. PubMed ID: 20237169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
    Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
    Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
    King AB; Armstrong DU
    Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.
    Derosa G; Cicero AF; Bertone G; Piccinni MN; Fogari E; Ciccarelli L; Fogari R
    Clin Ther; 2004 Aug; 26(8):1228-36. PubMed ID: 15476904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
    Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
    Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients.
    Mancia G; Omboni S; Agabiti-Rosei E; Casati R; Fogari R; Leonetti G; Montemurro G; Nami R; Pessina AC; Pirrelli A; Zanchetti A
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):926-31. PubMed ID: 10836728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
    Chogtu B; Singh NP; Chawla S; Gupta U
    Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
    Rodríguez A; Reviriego J; Polavieja P; Mesa J
    Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
    Abe M; Kikuchi F; Kaizu K; Matsumoto K
    Clin Nephrol; 2007 Nov; 68(5):287-94. PubMed ID: 18044260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
    Winkler K; Konrad T; Füllert S; Friedrich I; Destani R; Baumstark MW; Krebs K; Wieland H; März W
    Diabetes Care; 2003 Sep; 26(9):2588-94. PubMed ID: 12941723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
    Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.